Phase III clinical trial - Sarcomes
MULTISARC is a randomized multicenter study assessing whether high throughput molecular;analysis (next generation sequencing exome - NGS) is feasible in advanced soft tissue sarcoma;participants, that is, whether NGS can be conducted for a large proportion of participants, with;results available within reasonable delays (see primary endpoint).;À In parallel, MULTISARC aims to assess efficacy of an innovative treatment strategy guided by;high throughput molecular analysis (next generation sequencing exome, RNASeq [NGS],) in;participants with advanced soft-tissue sarcomas [STS].;À Randomization 1:1 with 1 participant randomized in experimental Arm NGS (treatment strategy;based on NGS [exome, RNASeq] results) and 1 participant randomized in standard Arm No NGS;(treatment strategy not based on NGS).;À High throughput analysis will be carried out using next generation sequencing.;À At the end of first-line treatment, participantÀs tumor profile of experimental Arm NGS (treatment;strategy based on NGS (exome, RNASeq) results) will be discussed within a multidisciplinary;tumor board (molecular tumor board-MTB) which aims at discussing the genomic profiles and at;providing a therapeutic decision for each participant.